日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.

对利拉夫格拉替尼的复发性耐药突变可指导 FGFR2 驱动肿瘤的治疗顺序。

Facchinetti Francesco, Hollebecque Antoine, Barbé Rémy, Jang Dong Man, Alonso-De-Castro Beatriz, Brayé Floriane, Bigot Ludovic, Nobre Catline, Da Silva Alice, Méteau Mélissandre, Delavigne Mathis, Soares Miguel, Italiano Antoine, Rodriguez Julieta, Mosele Fernanda, Beshiri Kristi, Ducreux Michel, Boilève Alice, Nikolaev Sergey, Alonso-Garcia Inmaculada, Vasseur Damien, Smolenschi Cristina, Bourien Héloise, Cotteret Sophie, Samaniego Juliette, Bernard Elsa, Nicotra Claudio, Ngo-Camus Maud, Nakazawa Seshiru, Tselikas Lambros, Badoual Cécile, André Fabrice, Eck Michael J, Olaussen Ken A, Loriot Yohann, Friboulet Luc

NOX4-derived oxidative DNA damage impairs thyroid differentiation through an epigenetic mechanism in BRAF-mutated radioactive iodine refractory papillary thyroid cancer cells.

NOX4 衍生的氧化性 DNA 损伤通过表观遗传机制损害 BRAF 突变的放射性碘难治性乳头状甲状腺癌细胞的甲状腺分化。

Radom Mickaëlle, Buffet Camille, Cazarin Juliana, Harinquet Marylin, de Faria Caroline Coelho, Brayé Floriane, Nobre Catline, Aglave Marine, Mesloub Yasmina, Dayris Thibault, Droin Nathalie, Godefroy Karine, Bani Mohamed-Amine, Ghuzlan Abir Al, Leboulleux Sophie, Lamartina Livia, Dupuy Corinne

Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development

解析癌症耐药机制:MATCH-R 研究最终报告,重点关注分子驱动因素和 PDX 构建

Vasseur, Damien; Bigot, Ludovic; Beshiri, Kristi; Flórez-Arango, Juan; Facchinetti, Francesco; Hollebecque, Antoine; Tselikas, Lambros; Aldea, Mihaela; Blanc-Durand, Felix; Gazzah, Anas; Planchard, David; Lacroix, Ludovic; Pata-Merci, Noémie; Nobre, Catline; Da Silva, Alice; Nicotra, Claudio; Ngo-Camus, Maud; Braye, Floriane; Nikolaev, Sergey I; Michiels, Stefan; Jules-Clement, Gérôme; Olaussen, Ken André; André, Fabrice; Scoazec, Jean-Yves; Barlesi, Fabrice; Ponce, Santiago; Soria, Jean-Charles; Besse, Benjamin; Loriot, Yohann; Friboulet, Luc

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

NVL-655 是一种选择性、脑渗透性抑制剂,可抑制多种 ALK 突变癌蛋白,包括劳拉替尼耐药化合物突变

Jessica J Lin #, Joshua C Horan #, Anupong Tangpeerachaikul #, Aurélie Swalduz, Augusto Valdivia, Melissa L Johnson, Benjamin Besse, D Ross Camidge, Toshio Fujino, Satoshi Yoda, Linh Nguyen-Phuong, Hayato Mizuta, Ludovic Bigot, Catline Nobre, Jii Bum Lee, Mi Ra Yu, Scot Mente, Yuting Sun, Nancy E Ko

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies

了解并克服FGFR2驱动型恶性肿瘤对选择性FGFR抑制剂的耐药性

Francesco Facchinetti ,Yohann Loriot ,Floriane Brayé ,Damien Vasseur ,Rastislav Bahleda ,Ludovic Bigot ,Rémy Barbé ,Catline Nobre ,David Combarel ,Stefan Michiels ,Antoine Italiano ,Cristina Smolenschi ,Lambros Tselikas ,Jean-Yves Scoazec ,Santiago Ponce-Aix ,Benjamin Besse ,Fabrice André ,Ken A Olaussen ,Antoine Hollebecque ,Luc Friboulet

A severe pediatric life-threatening metabolic ketoacidosis

一种危及生命的严重儿童代谢性酮症酸中毒

Roulland, Charlotte; Le Pallec, Catline; Faucon, Caroline; Andre, Camille O; Arion, Alina; Goyer, Isabelle; Brossier, David